Orgenesis Inc. (ORGS)
OTCMKTS
· Delayed Price · Currency is USD
0.2500
-0.5000 (-66.67%)
At close: Dec 5, 2025
Orgenesis Employees
Orgenesis had 146 employees as of December 31, 2023. The number of employees decreased by 21 or -12.57% compared to the previous year.
Employees
146
Change (1Y)
-21
Growth (1Y)
-12.57%
Revenue / Employee
$6,158
Profits / Employee
-$235,699
Market Cap
1.64M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| Zomedica | 152 |
Orgenesis News
- 9 months ago - Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies - Accesswire
- 11 months ago - Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings - Accesswire
- 1 year ago - Orgenesis GAAP EPS of $1.93, revenue of $0.3M - Seeking Alpha
- 1 year ago - Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga
- 1 year ago - Orgenesis announces 1-for-10 reverse stock split to regain Nasdaq compliance - Seeking Alpha
- 1 year ago - Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia - GlobeNewsWire
- 1 year ago - Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally - GlobeNewsWire
- 1 year ago - Orgenesis Provides Business Update for the First Quarter of 2024 - GlobeNewsWire